Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain.

Osumili, Beatrice; Artime, Esther; Mitchell, Beth; Rubio-de Santos, Miriam; Díaz-Cerezo, Silvia; Giménez, Marga; Spaepen, Erik; Sharland, Helen; Valentine, William J

Osumili, Beatrice; Artime, Esther; Mitchell, Beth; Rubio-de Santos, Miriam; Díaz-Cerezo, Silvia; Giménez, Marga; Spaepen, Erik; Sharland, Helen; Valentine, William J.

Afiliación

Osumili B; Eli Lilly and Company Limited, Bracknell, UK.
Artime E; Lilly España, Madrid, Spain.
Mitchell B; Eli Lilly and Company, Indianapolis, USA.
Rubio-de Santos M; Lilly España, Madrid, Spain.
Díaz-Cerezo S; Lilly España, Madrid, Spain.
Giménez M; Diabetes Unit, Endocrinology and Nutrition Department, IMDM, Hospital Clínic i Universitari de Barcelona, Barcelona, Spain.
Spaepen E; HaaPACS GmbH, Schriesheim, Germany.
Sharland H; Ossian Health Economics and Communications GmbH, Bäumleingasse 20, 4051, Basel, Switzerland.
Valentine WJ; Ossian Health Economics and Communications GmbH, Bäumleingasse 20, 4051, Basel, Switzerland. valentine@ossianconsulting.com.

Diabetes Ther ; 13(4): 775-794, 2022 Apr.

Article en En | MEDLINE | ID: mdl-35297026

Palabras clave

Budget impact; Cost-offset; Diabetes mellitus; Healthcare cost; Healthcare resource; Injectable glucagon; Insulin; Nasal glucagon; Severe hypoglycemia; Spain

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Diabetes Ther Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google